DGAP-News

EVOTEC SE REPORTS RESULTS FOR THE FIRST QUARTER 2021 AND PROVIDES CORPORATE UPDATE - Seite 2

POSITIVE DEVELOPMENT WITH SEVERAL NEW AND EXPANDED PARTNERSHIPS; JUST - EVOTEC BIOLOGICS FURTHER GAINING MOMENTUM

• Multiple new and extended partnerships and alliances (e.g. with Annexon, Chinook Therapeutics, Related Sciences, Takeda, The Mark Foundation, ...)
  • New development collaborations and INDiGO contracts signed (e.g. Riboscience, Step Pharma, ...)
• New iPSC- multi-year partnership with the Medical Center Hamburg Eppendorf ("UKE")
• Bristol Myers Squibb extend partnership in the field of targeted protein degradation
• Just - Evotec Biologics continuing on its success course: progress of the first J.POD^(R) facility in Redmond on schedule; construction of first European "J.POD^(R) 2 EU" expected to start in H2 2021
• Partnership on oncology project EVT801 with Kazia Therapeutics (after period-end)
• New BRIDGEs ("beLAB2122" and "beLAB1407" (after period-end))
• Projects entering into clinical phases (EVT894 (Chik-V); Immuno-oncology project A2a receptor antagonist (Exscientia))

CORPORATE HIGHLIGHTS

• Implementation of next long-term strategic framework Action Plan 2025 "The data-driven R&D Autobahn to Cures"
• Chairman of the Supervisory Board of Evotec to retire from office effective as of the end of the Annual General Meeting on 15 June 2021 (after period-end)

GUIDANCE FOR FULL-YEAR 2021 CONFIRMED

• Business outlook for 2021 confirmed and mid-term targets given for the first time
• Group revenues expected to be in a range of € 550 - 570 m (€ 565 - 585 m at constant exchange rates) (2020: € 500.9 m)
• Adjusted Group EBITDA expected to be in the range of € 105 - 120 m (€ 115 - 130 m at constant exchange rates) (2020: € 106.6 m)
• Unpartnered research and development expenses expected to be in a range of € 50 - 60 m (2020: € 46.4 m)